- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03244137
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease is a leading cause of mortality worldwide.
It is a systemic disease which includes pulmonary, cardiac, muscular, digestive and cognitive impairments.
Pulmonary rehabilitation is a symptomatic treatment to reduce dyspnea and functional incapacity. However, it effects on cognitive dysfunction are not well known.
The aim of this study is to assess the effects of a comprehensive pulmonary rehabilitation program on cognitive dysfunction in patients with severe to very severe chronic obstructive pulmonary disease using the Montreal Cognitive Assessment tool.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bois-Guillaume, France, 76230
- Bonnevie
-
Le Havre, France, 76600
- Médrinal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18years;
- Chronic obstructive pulmonary disease stade III to IV;
- Referred for pulmonary rehabilitation.
Non Inclusion Criteria:
- Pregnancy or likely to be;
- History of psychiatric, neuro-vascular, cognitive disease or cranial trauma;
- Active alcoholism;
- Guardianship;
- Hospitalisation for acute exacerbation of chronic obstructive pulmonary disease in the previous 4 weeks;
Exclusion Criteria:
- Interruption of the pulmonary rehabilitation program > 15 days;
- Disruption of the training before the 18th session;
- Less than 18 sessions in four month.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pulmonary rehabilitation
The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
|
See group description.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline cognitive function
Time Frame: Cognitive function is assessed at the beginning of the rehabilitation program : day 0
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed at the beginning of the rehabilitation program : day 0
|
Cognitive function after pulmonary rehabilitation
Time Frame: Cognitive function is assessed at the end of the rehabilitation program : day 60
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed at the end of the rehabilitation program : day 60
|
Cognitive function : follow up
Time Frame: Cognitive function is assessed 3 month after rehabilitation : day 150
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Cognitive function is assessed 3 month after rehabilitation : day 150
|
Change in cognitive function from baseline to the end of pulmonary rehabilitation
Time Frame: Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
|
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up
Time Frame: Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool
|
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety and depression : baseline
Time Frame: Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
|
Anxiety and depression : end of pulmonary rehabilitation
Time Frame: Anxiety and depression are assessed at the end of the rehabilitation program : day 60
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assessed at the end of the rehabilitation program : day 60
|
Anxiety and depression : follow up
Time Frame: Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
|
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
|
Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
|
Quality of life : baseline
Time Frame: Quality of life is assessed at the beginning of the rehabilitation program : day 0
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed at the beginning of the rehabilitation program : day 0
|
Quality of life : end of pulmonary rehabilitation
Time Frame: Quality of life is assessed at the end of the rehabilitation program : day 60
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed at the end of the rehabilitation program : day 60
|
Quality of life : follow-up
Time Frame: Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
|
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
|
Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
|
Functional capacity (six-minute stepper test) : baseline
Time Frame: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity is assessed with the six-minute stepper test
|
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity (six-minute stepper test) : end of pulmonary rehabilitation
Time Frame: Functional capacity is assessed at the end of the rehabilitation program : day 60
|
Functional capacity is assessed with the six-minute stepper test
|
Functional capacity is assessed at the end of the rehabilitation program : day 60
|
Functional capacity (six-minute walk test) : baseline
Time Frame: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Functional capacity is assessed with the six-minute walk test
|
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
|
Adherence
Time Frame: Adherence is assessed at the end of the rehabilitation program : day 60
|
Adherence to the pulmonary rehabilitation program is assessed by the following equation : number of session performed divided by the number of scheduled sessions
|
Adherence is assessed at the end of the rehabilitation program : day 60
|
Relation between the cognitive function and the respiratory function (forced expiratory volume in 1 second)
Time Frame: The relation is assessed between baseline demographic data at day 0
|
Cognitive function is assessed with the Montreal Cognitive Assessement tool and respiratory function is assessed with spirometric evaluation
|
The relation is assessed between baseline demographic data at day 0
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cuvelier Antoine, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
- Study Chair: Muir Jean-François, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; ADIR Association, Bois-Guillaume, France.
- Study Chair: Tardif Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France
- Study Chair: Viacroze Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
- Study Chair: Debeaumont David, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France.
- Study Chair: Patout Maxime, MD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
- Study Chair: Lamia Bouchra, Prof, PhD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France.
- Study Chair: Quieffin Jean, MD, Service de pneumologie, Hôpital Jacques Monod 76290 Montivilliers.
- Study Chair: Prieur Guillaume, PT, MsC, Service de pneumologie, Groupe Hospitalier du Havre, Fr
- Study Chair: Médrinal Clément, PT, MsC, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France. Service de réanimation, Groupe Hospitalier du Havre, France
- Study Chair: Gravier Francis-Edouard, PT, ADIR Association, Bois-Guillaume, France
- Study Chair: Bonnevie Tristan, PT, MsC, ADIR Association, Bois-Guillaume, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-COPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Guy's and St Thomas' NHS Foundation TrustSuspendedChronic Obstructive Pulmonary Disease SevereUnited Kingdom
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
Clinical Trials on Pulmonary rehabilitation
-
Universidade Federal de Santa MariaCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Faculty of Medicine, SousseCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
Istanbul Medipol University HospitalRecruitingLung Diseases | Bronchiectasis | Lung Diseases, Interstitial | Pulmonary RehabilitationTurkey
-
La Trobe UniversityMonash University; The Alfred; Austin HealthCompletedChronic Obstructive Pulmonary DiseaseAustralia
-
Istanbul Medipol University HospitalCompletedEmphysema | Bronchoscopic Lung Volume Reduction | Hospital-based Pulmonary Rehabilitation | Home-based Pulmonary RehabilitationTurkey
-
Aveiro UniversityCentro Hospitalar do Baixo VougaRecruitingChronic Obstructive Pulmonary Disease | Interstitial Lung DiseasePortugal
-
National Cheng-Kung University HospitalCompletedTelerehabilitation | Pulmonary Rehabilitation | Compliance, Patient | COPD | Cardiopulmonary Exercise TestTaiwan
-
Hospital Clinic of BarcelonaSociedad Española de Neumología y Cirugía TorácicaUnknownNon-cystic Fibrosis Bronchiectasis
-
University of MaltaCompletedInterstitial Lung DiseaseMalta
-
Copenhagen University Hospital, HvidovreCopenhagen University Hospital Bispebjerg-Frederiksberg; Copenhagen University... and other collaboratorsRecruiting